Abstract:<p>Hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising treatment strategy for patients with peritoneal metastasis of ovarian cancer. Heat shock proteins (HSPs) play an important role in cellular stress during HIPEC treatment. The aim of the present study was to investigate whether paclitaxel can exert antitumor effects by inhibiting heat shock protein 27 (HSP27) expression during HIPEC treatment. Cell viability was detected by CCK8 assay. We used Western blot analysis to detect HSP27 expression under hyperthermia conditions with or without paclitaxel in SKOV3 cells. To further examine the role of HSP27 in the apoptosis, Bcl-2, Bax and Caspase-3 protein expression were additionally determined after reducing HSP27 levels using an siRNA strategy, and apoptosis was detected using the Annexin V/PI assay. The upregulation of HSP27 expression was accompanied with a rise in temperature. In addition, HSP27 could promote Bcl-2 expression, inhibit Bax and Caspase-3 expression, reduce the Bax / Bcl-2 ratio markedly in SKOV3 cells. Furthermore, paclitaxel could upregulate the Bax / Bcl-2 ratio by inhibiting HSP27 expression, and in turn, promoting apoptosis due to hyperthermia. Paclitaxel could also promote apoptosis by inhibiting HSP27 in SKOV3 cells. Our results demonstrate a synergistic effect between paclitaxel and hyperthermia at the cellular level.</p>

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether paclitaxel can enhance the sensitivity to hyperthermia by inhibiting the expression of heat shock protein 27 (HSP27) in ovarian cancer cells (SKOV3 cell line). Specifically, the study aims to explore whether paclitaxel can improve the anti - tumor effect during hyperthermic intraperitoneal chemotherapy (HIPEC), especially by regulating the expression levels of apoptosis - related proteins such as Bcl - 2, Bax and Caspase - 3 through inhibiting HSP27 expression. ### Brief Introduction of the Paper Background Ovarian cancer is a common female cancer with a relatively high incidence and mortality rate, especially in the case of peritoneal metastasis. Due to the relative resistance to systemic chemotherapy, this type of cancer often has a poor prognosis. In recent years, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been increasingly used to treat peritoneal metastatic ovarian cancer and has achieved encouraging results. However, tumor cells can protect themselves from extreme temperatures through different mechanisms, a phenomenon known as thermotolerance. Heat shock proteins (HSPs), especially HSP27, which is one of the members of the small - molecule heat shock protein family, play an important role in the cellular stress response, being able to promote protein folding and maintain its native structure, reduce apoptosis, and enhance cell proliferation, migration and angiogenesis. ### Research Objectives The research objective of this paper is to explore whether paclitaxel can enhance the sensitivity of SKOV3 cells to hyperthermia by inhibiting the expression of HSP27, thereby improving the treatment effect of HIPEC. The study evaluated the combined effect of paclitaxel and hyperthermia by detecting changes in cell viability, HSP27 expression and apoptosis - related proteins (Bcl - 2, Bax and Caspase - 3). ### Main Findings 1. **Effects of Temperature on Cell Viability and HSP27 Expression**: When the temperature reaches 43°C or above, cell viability decreases significantly, and at the same time, the expression of HSP27 increases significantly. 2. **HSP27 Knock - down Enhances Apoptosis**: After knocking down HSP27 using siRNA technology, the apoptosis rate of cells increases significantly, especially under the condition of 43°C. 3. **Paclitaxel Inhibits HSP27 Expression and Reduces Cell Viability**: After treatment with different concentrations of paclitaxel, the expression of HSP27 is inhibited and cell viability decreases. 4. **Combined Effect of Paclitaxel and Hyperthermia**: When paclitaxel is used in combination with hyperthermia, the expression of Bcl - 2 decreases, the expressions of Bax and Caspase - 3 increase, and the apoptosis rate of cells increases significantly, indicating a synergistic effect between the two. ### Conclusion The study shows that paclitaxel enhances the sensitivity of SKOV3 cells to hyperthermia by inhibiting the expression of HSP27 and increases the apoptosis rate, showing a synergistic effect between the two at the cellular level. This provides a new idea and a potential treatment strategy for HIPEC in the treatment of ovarian cancer.

Paclitaxel increases sensitivity of SKOV3 cells to hyperthermia by inhibiting heat shock protein 27

Induction of Apoptosis by a Combination of Paclitaxel and Carboplatin in the Presence of Hyperthermia.

Enhancement of Osteosarcoma Cell Sensitivity to Cisplatin Using Paclitaxel in the Presence of Hyperthermia

Silencing of Heat Shock Protein 27 Increases the Radiosensitivity of Non‑small Cell Lung Carcinoma Cells.

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia to cure advanced ovarian cancer

Establishment of a new paclitaxel resistant cell line of human ovarian carcinoma and preliminary observation of its biology.

Hyperthermia enhances the efficacy of chemotherapeutic drugs in heat-sensitive cells through interfering with DNA damage repair

Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells with Acquired Paclitaxel Resistance

Targeted Inhibition of Transient Activation of the EGFR-mediated Cell Survival Pathway Enhances Paclitaxel-Induced Ovarian Cancer Cell Death

Down-regulation of UTP23 Promotes Paclitaxel Resistance and Predicts Poorer Prognosis in Ovarian Cancer.

Effects of TP regimen combined with intraperitoneal hyperthermic perfusion chemotherapy on immune function, quality of life and prognosis of patients with advanced ovarian cancer

Curcumin enhances the anti-cancer efficacy of paclitaxel in ovarian cancer by regulating the miR-9-5p/BRCA1 axis

Preparation of thermosensitive liposomes containing paclitaxel and their anticancer effect

Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplanta-tion tumor

PGAM1 Modulates Paclitaxel-Resistance in Ovarian Cancer Cells Through Controlling Pyruvic Acid Production in Glycolysis

Paclitaxel hyperthermia suppresses gastric cancer migration through MiR-183-5p/PPP2CA/AKT/GSK3β/β-catenin axis

Expression of Bcl-Xl and Survivin in Inhibition of Dexamethasone on Paclitaxel-induced Apoptosis in Human Ovarian Cancer Cell Line SKOV-3

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy

HSP27 modulates tumoural immune evasion by enhancing STAT3-mediated upregulation of PD-L1 and NLRC5 in ovarian cancer

HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation

Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases